Understanding treatment, utilization, and costs in advanced/metastatic (Adv/Met) gastric or gastroesophageal junction cancer (GC/GEJC): Implications for episodic payment models.

被引：0
|
作者：
Kelly, Ronan Joseph
Le, Hannah
Wu, Sze-Jung
Laurie, Melissa
Raval, Amit D.
Shi, Qian
Korytowsky, Beata
机构：
[1] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[2] Bristol Myers Squibb Co, Lawrenceville, NJ USA
[3] HealthCore, Wilmington, DE USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e16035
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16035
引用
下载
收藏
页数：2
相关论文
共 50 条
  • [1] DIRECT AND INDIRECT COSTS ASSOCIATED WITH UNRESECTABLE ADVANCED OR METASTATIC (ADV/MET) GASTRIC CANCER (GC), GASTROESOPHAGEAL JUNCTION CANCER (GEJC) AND ESOPHAGEAL ADENOCARCINOMA (EAC) FOR PATIENTS AND THEIR CAREGIVERS
    Hall, J.
    Khela, K.
    Bertwistle, D.
    Xiao, H.
    VALUE IN HEALTH, 2020, 23 : S482 - S483
  • [2] Comparative effectiveness of nivolumab (NIVO) relative to standard of care (SOC) for advanced/metastatic (adv/met) gastric or gastroesophageal junction cancer (GC/GEJC): A simulated treatment comparison (STC).
    Chau, Ian
    Ayers, Dieter
    Goring, Sarah
    Keeping, Sam
    Goulding, Rebecca
    Cope, Shannon
    Chamot, Eric
    Le, Hannah
    Xu, Yanqing
    Abraham, Pranav
    Korytowsky, Beata
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [3] Translating molecular subtypes of gastric and gastroesophageal junction cancer (GC and GEJC) to the metastatic (met) setting: Prevalence and outcome dataTranslating molecular subtypes of gastric and gastroesophageal junction cancer (GC and GEJC) to the metastatic (met) setting: prevalence and outcome data.
    Gardeazabal, Itziar
    Hierro, Cinta
    Viaplana, Cristina
    Nuciforo, Paolo
    Vivancos, Ana
    Mercade, Teresa Macarulla
    Garralda, Elena
    Eugenia Semidey, Maria
    Grau Bejar, Juan Francisco
    Dienstmann, Rodrigo
    Landolfi, Stefania
    Alsina, Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] TREATMENT PATTERNS AND PERFORMANCE STATUS IN UNRESECTABLE ADVANCED OR METASTATIC (ADV/MET) GASTRIC CANCER (GC), GASTROESOPHAGEAL JUNCTION CANCER (GEJC) AND ESOPHAGEAL ADENOCARCINOMA (EAC) PATIENTS RECEIVING FIRST LINE (1L) TREATMENT
    Hall, J.
    Khela, K.
    Middleton-Dalby, C.
    Bertwistle, D.
    Xiao, H.
    VALUE IN HEALTH, 2020, 23 : S485 - S485
  • [5] Novel Frontiers of Treatment for Advanced Gastric or Gastroesophageal Junction Cancer (GC/GEJC): Will Immunotherapy Be a Future Direction?
    Bai, Rilan
    Chen, Naifei
    Liang, Tingting
    Li, Lingyu
    Lv, Zheng
    Lv, Xiaomin
    Cui, Jiuwei
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [6] The humanistic burden reported by patients with unresectable locally advanced or metastatic (adv/met) gastric cancer (GC), gastroesophageal junction cancer (GEJC) and esophageal adenocarcinoma (EAC): An international real-world survey
    Hall, J. P.
    Khela, K.
    Moon, R.
    Middleton-Dalby, C.
    Bertwistle, D.
    Xiao, H.
    ANNALS OF ONCOLOGY, 2020, 31 : S918 - S918
  • [7] What is the outcome of receiving subsequent therapy among patients (pts) with advanced/metastatic (Adv/Met) gastric or gastroesophageal junction cancer (GC/GEJC)? Experience from electronic health records (EHR).
    Le, Dung T.
    Janjigian, Yelena Yuriy
    Ott, Patrick Alexander
    Korytowsky, Beata
    Le, Hannah
    Trong Kim Le
    Zhang, Ying
    Maglinte, Gregory
    Patel, Dhiren
    Shangguan, Tong
    Chau, Ian
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] The potential drug cost impact of nivolumab (N) in patients with advanced/metastatic gastric cancer (GC) or gastroesophageal junction cancer (GEJC) in Canada.
    Virik, Kiran
    Wilson, Robert B.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [9] A phase Ib/II study of fruquintinib in combination with SOX and toripalimab as first-line treatment for advanced metastatic gastric/gastroesophageal junction adenocarcinoma (GC/GEJC).
    Meng, Xiangrui
    Shan, Zhengzheng
    Guan, Lulu
    Dao, Xin
    Fan, Qingxia
    Wang, Feng
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 335 - 335
  • [10] Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab (TIS) in patients (pts) with unresectable locally advanced or metastatic gastric cancer/gastroesophageal junction cancer (GC/GEJC)
    Chen, Zhendong
    Bai, Yuxian
    Zhang, Tao
    Ying, Jieer
    Lin, Xiaoyan
    Yang, Liu
    Wang, Jun
    Zhang, Juan
    Yu, Fan
    Fei, Cong
    Huang, Ruiqi
    Li, Jin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
12345